

# Jeremy Millar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1534308/publications.pdf>

Version: 2024-02-01

183  
papers

6,604  
citations

117625

34  
h-index

69250

77  
g-index

185  
all docs

185  
docs citations

185  
times ranked

7328  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. <i>Lancet Oncology</i> , The, 2005, 6, 659-668.	10.7	876
2	Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. <i>Lancet Oncology</i> , The, 2007, 8, 475-487.	10.7	843
3	Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade. <i>Journal of Immunology</i> , 2005, 175, 2741-2753.	0.8	431
4	Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 464-473.	10.7	392
5	Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. <i>BJU International</i> , 2012, 109, 22-29.	2.5	391
6	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 2020, 21, 1331-1340.	10.7	197
7	15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 57-64.	0.8	196
8	Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. <i>Radiotherapy and Oncology</i> , 2008, 88, 10-19.	0.6	174
9	Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06) Tj ETQq1 1 0.784314 rgBT /O The, 2016, 17, 727-737.	10.7	172
10	Human immunodeficiency virus-related primary central nervous system lymphoma. <i>Cancer</i> , 2004, 100, 2627-2636.	4.1	123
11	A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy vs Adjuvant Versus Early Salvage (RAVES) trial. <i>BJU International</i> , 2014, 113, 7-12.	2.5	104
12	In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. <i>Prostate</i> , 2014, 74, 458-468.	2.3	103
13	Urethral strictures following high-dose-rate brachytherapy for prostate cancer: Analysis of risk factors. <i>Brachytherapy</i> , 2013, 12, 50-55.	0.5	81
14	The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. <i>BJU International</i> , 2015, 115, 50-56.	2.5	80
15	Effect of Aspirin on Cancer Incidence and Mortality in Older Adults. <i>Journal of the National Cancer Institute</i> , 2021, 113, 258-265.	6.3	80
16	Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. <i>Medical Journal of Australia</i> , 2013, 198, 540-545.	1.7	74
17	High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. <i>Brachytherapy</i> , 2010, 9, 27-35.	0.5	72
18	The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. <i>BJU International</i> , 2013, 111, E158-66.	2.5	61

#	ARTICLE	IF	CITATIONS
19	Long-Term Outcomes of Patients with Localized Rectal Cancer Treated with Chemoradiation or Radiotherapy Alone Because of Medical Inoperability or Patient Refusal. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 2032-2039.	1.3	59
20	Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2004, 73, 33-38.	0.6	52
21	Effect of Radiotherapy Volume and Dose on Secondary Cancer Risk in Stage I Testicular Seminoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 853-858.	0.8	52
22	Effect of Intensity-Modulated Pelvic Radiotherapy on Second Cancer Risk in the Postoperative Treatment of Endometrial and Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 539-545.	0.8	51
23	A biochemical definition of cure after brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 149, 64-69.	0.6	48
24	Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 1113-1122.	1.3	47
25	Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1192-1201.	10.7	45
26	Factors associated with adherence to physical activity guidelines in patients with prostate cancer. <i>Psycho-Oncology</i> , 2013, 22, 2478-2486.	2.3	44
27	Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients. <i>European Journal of Haematology</i> , 2017, 99, 423-430.	2.2	43
28	The Victorian Lung Cancer Registry Pilot: Improving the Quality of Lung Cancer Care Through the Use of a Disease Quality Registry. <i>Lung</i> , 2014, 192, 749-758.	3.3	42
29	Cleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry â€œ Victoria. <i>Prostate International</i> , 2016, 4, 145-151.	2.3	41
30	The state of <sc>TRUS</sc> biopsy sepsis: readmissions to Victorian hospitals with <sc>TRUS</sc> biopsyâ€related infection over 5 years. <i>BJU International</i> , 2015, 116, 49-53.	2.5	40
31	Source position verification and dosimetry in HDR brachytherapy using an EPID. <i>Medical Physics</i> , 2013, 40, 111706.	3.0	39
32	Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry. <i>BJU International</i> , 2014, 114, 680-690.	2.5	39
33	Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. <i>Psycho-Oncology</i> , 2013, 22, 2169-2176.	2.3	36
34	Quality indicators for radiation oncology. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 249-257.	1.8	36
35	Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes. <i>BMJ Open</i> , 2017, 7, e017006.	1.9	35
36	Caregiversâ€™ information needs and their â€™experiences of careâ€™ during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 4177-4186.	2.2	34

#	ARTICLE	IF	CITATIONS
37	The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers. <i>Supportive Care in Cancer</i> , 2017, 25, 3447-3456.	2.2	33
38	An integrated system for clinical treatment verification of HDR prostate brachytherapy combining source tracking with pretreatment imaging. <i>Brachytherapy</i> , 2018, 17, 111-121.	0.5	32
39	An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 351-357.	0.8	31
40	Quality of care achievements of the Prostate Cancer Outcomes Registry—Victoria. <i>Medical Journal of Australia</i> , 2016, 204, 319-319.	1.7	31
41	Development of an International Prostate Cancer Outcomes Registry. <i>BJU International</i> , 2016, 117, 60-67.	2.5	31
42	Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 185-194.	1.2	31
43	Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1082-1087.	0.8	30
44	Comparison of oncological and health-related quality of life outcomes between open and robot-assisted radical prostatectomy for localised prostate cancer – findings from the population-based Victorian Prostate Cancer Registry. <i>BJU International</i> , 2016, 118, 563-569.	2.5	29
45	A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 81-88.	1.8	28
46	What to do for prostate cancer patients with a rising PSA?—a survey of Australian practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 986-991.	0.8	27
47	Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2014, 15, 256-266.	1.9	26
48	Size of anal squamous cell carcinomas at diagnosis: a retrospective case series. <i>International Journal of STD and AIDS</i> , 2013, 24, 879-882.	1.1	25
49	The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period. <i>Journal of Cancer Survivorship</i> , 2017, 11, 329-338.	2.9	25
50	Blindness in patients after external beam irradiation for pituitary adenomas: Two cases occurring after small daily fractional doses. <i>Clinical Oncology</i> , 1991, 3, 291-294.	1.4	23
51	Prostate-Specific Antigen Bounce After Permanent Iodine-125 Prostate Brachytherapy—An Australian Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 179-187.	0.8	23
52	Rural residency and prostate cancer specific mortality: results from the Victorian Radical Prostatectomy Register. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 449-454.	1.8	22
53	Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry—Victoria. <i>Medical Journal of Australia</i> , 2018, 208, 439-443.	1.7	22
54	Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone. <i>Brachytherapy</i> , 2019, 18, 313-321.	0.5	22

#	ARTICLE	IF	CITATIONS
55	A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. <i>BMC Cancer</i> , 2016, 16, 607.	2.6	21
56	A method for verification of treatment delivery in HDR prostate brachytherapy using a flat panel detector for both imaging and source tracking. <i>Medical Physics</i> , 2016, 43, 2435-2442.	3.0	20
57	Trends in Conservative Management for Low-risk Prostate Cancer in a Population-based Cohort of Australian Men Diagnosed Between 2009 and 2016. <i>European Urology Oncology</i> , 2021, 4, 319-322.	5.4	20
58	Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study. <i>BJU International</i> , 2017, 120, 6-14.	2.5	19
59	Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 378-388.	3.9	19
60	What defines intermediate-risk prostate cancer? Variability in published prognostic models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 11-18.	0.8	18
61	Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 18-30.	1.8	18
62	Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 72-76.	0.6	18
63	Understanding the Relationship Between Interactive Optimisation and Visual Analytics in the Context of Prostate Brachytherapy. <i>IEEE Transactions on Visualization and Computer Graphics</i> , 2018, 24, 319-329.	4.4	18
64	Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer. <i>BJU International</i> , 2017, 120, 35-42.	2.5	17
65	Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial. <i>Trials</i> , 2017, 18, 451.	1.6	17
66	Development of Indicators to Assess Quality of Care for Prostate Cancer. <i>European Urology Focus</i> , 2018, 4, 57-63.	3.1	17
67	Forecasting annual incidence and mortality rate for prostate cancer in Australia until 2022 using autoregressive integrated moving average (ARIMA) models. <i>BMJ Open</i> , 2019, 9, e031331.	1.9	17
68	Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia. <i>BMC Urology</i> , 2016, 16, 54.	1.4	16
69	Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e827-e834.	1.9	16
70	The influence of the dwell time deviation constraint (DTDC) parameter on dosimetry with IPSA optimisation for HDR prostate brachytherapy. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2015, 38, 55-61.	1.3	15
71	Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 61-66.	0.8	15
72	The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs. <i>Nature Reviews Urology</i> , 2020, 17, 499-512.	3.8	15

#	ARTICLE	IF	CITATIONS
73	Prostate cancer in Victoria in 1993: patterns of reported management. Medical Journal of Australia, 2000, 172, 270-274.	1.7	14
74	Contemporary management of renal cell carcinoma (<scp>RCC</scp>) in <scp>V</scp>ictoria: implications for longer term outcomes and costs. BJU International, 2013, 112, 36-43.	2.5	14
75	Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the <scp>P</scp>rostate <scp>C</scp>ancer <scp>R</scp>egistry. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 247-254.	1.8	14
76	Menâ€™s perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia. BMC Cancer, 2017, 17, 704.	2.6	14
77	A whole of populationâ€™based series of radical prostatectomy in Victoria, 1995 to 2000. Australian and New Zealand Journal of Public Health, 2009, 33, 527-533.	1.8	13
78	An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review. Radiation Oncology, 2017, 12, 56.	2.7	13
79	Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 530.e7-530.e13.	1.6	13
80	Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: an update. ANZ Journal of Surgery, 2018, 88, 1037-1042.	0.7	13
81	The trajectory of patients who die from metastatic prostate cancer: a populationâ€™based study. BJU International, 2019, 123, 19-26.	2.5	13
82	Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand. JAMA Network Open, 2021, 4, e2129647.	5.9	13
83	A double exposed portal image comparison between electronic portal imaging hard copies and port films in radiation therapy treatment setup confirmation to determine its clinical application in a radiotherapy center. International Journal of Radiation Oncology Biology Physics, 2001, 49, 191-198.	0.8	12
84	Disease-specific quality of life among patients with localized prostate cancer: an Australian perspective. BJU International, 2006, 97, 1179-1183.	2.5	12
85	â€™GAPâ€™ in radiotherapy services in Australia and New Zealand in 2009. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 287-297.	1.8	12
86	Systematic Review of Quality Improvement Interventions Directed at Cancer Specialists. Journal of Clinical Oncology, 2013, 31, 1583-1591.	1.6	12
87	Underâ€™utilisation of highâ€™doseâ€™rate brachytherapy boost in men with intermediateâ€™high risk prostate cancer treated with external beam radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 256-261.	1.8	12
88	Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method. Radiotherapy and Oncology, 2018, 128, 308-314.	0.6	12
89	3D Radiotherapy Can Be Safely Combined With Sandwich Systemic Gemcitabine Chemotherapy in the Management of Pancreatic Cancer: Factors Influencing Outcome. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1438-1446.	0.8	11
90	Predictors of prostate cancer specific mortality after radical prostatectomy: 10â€™year oncologic outcomes from the Victorian Radical Prostatectomy Registry. BJU International, 2015, 116, 66-72.	2.5	11

#	ARTICLE	IF	CITATIONS
91	Quality Indicators for Global Benchmarking of Localized Prostate Cancer Management. <i>Journal of Urology</i> , 2018, 200, 319-326.	0.4	11
92	Are We Choosing Wisely in Radiation Oncology Practice—Findings From an Australian Population-Based Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1012-1016.	0.8	11
93	Patterns of care for prostate cancer treatment and improving outcomes—are national registries the answer?. <i>BJU International</i> , 2021, 128 Suppl 1, 6-8.	2.5	11
94	Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (<scp>HIV</scp>)—positive population: experience in an <scp>A</scp>ustralian major <scp>HIV</scp> centre. <i>BJU International</i> , 2015, 116, 5-10.	2.5	10
95	HIV and renal cell carcinoma: Experience in an Australian statewide HIV center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 188-193.	1.1	10
96	Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 318-337.	0.8	10
97	Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case—control study. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 305-310.	3.9	10
98	3D catheter reconstruction in HDR prostate brachytherapy for pre-treatment verification using a flat panel detector. <i>Physica Medica</i> , 2017, 39, 121-131.	0.7	10
99	Diagnosis of thymoma by fine-needle aspiration cytology: Light and electron microscopic study of a case. <i>Diagnostic Cytopathology</i> , 1987, 3, 166-169.	1.0	9
100	Rectal cancer in Victoria in 1994: Patterns of reported management. <i>ANZ Journal of Surgery</i> , 2002, 72, 265-270.	0.7	9
101	Prevalence of Baseline Erectile Dysfunction (ED) in an Australian Cohort of Men with Localized Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2015, 12, 1267-1274.	0.6	9
102	Predictors of real—world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone—sensitive prostate cancer. <i>Internal Medicine Journal</i> , 2022, 52, 1339-1346.	0.8	9
103	MANAGEMENT OF MUSCLE-INVASIVE BLADDER CANCER IN VICTORIA, 1990-1995. <i>ANZ Journal of Surgery</i> , 2006, 76, 113-119.	0.7	8
104	Geospatial and temporal variation of prostate cancer incidence. <i>Public Health</i> , 2021, 190, 7-15.	2.9	8
105	Musculoskeletal Responses to Exercise Plus Nutrition in Men with Prostate Cancer on Androgen Deprivation: A 12-Month RCT. <i>Medicine and Science in Sports and Exercise</i> , 2021, 53, 2054-2065.	0.4	8
106	Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings. <i>Asian Journal of Urology</i> , 2019, 6, 321-329.	1.2	7
107	Establishing a global quality of care benchmark report. <i>Health Informatics Journal</i> , 2021, 27, 146045822110157.	2.1	7
108	Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5018-5018.	1.6	7

#	ARTICLE	IF	CITATIONS
109	A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. <i>Cancers</i> , 2021, 13, 5815.	3.7	7
110	Comparison of Patient-Reported Quality-of-Life and Complications in Men With Prostate Cancer, Between Two Modes of Administration. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 284-289.	1.9	6
111	Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution. <i>Brachytherapy</i> , 2017, 16, 313-322.	0.5	6
112	Early-onset baldness and the risk of aggressive prostate cancer: findings from a case-control study. <i>Cancer Causes and Control</i> , 2018, 29, 93-102.	1.8	6
113	Choosing Wisely in radiation therapy for breast cancer: Time lag in adoption of hypofractionated radiation therapy in Victoria. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 224-232.	1.8	6
114	MANAGEMENT OF SUPERFICIAL BLADDER CANCER IN VICTORIA: 1990 AND 1995. <i>ANZ Journal of Surgery</i> , 2005, 75, 270-274.	0.7	5
115	Low Uptake of Upfront Autologous Transplantation for Myeloma in a Jurisdiction With Universal Health Care Coverage: A Population-Based Patterns of Care Study in Australia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 61-67.	0.4	5
116	Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms—a whole of population study. <i>Prostate International</i> , 2015, 3, 75-79.	2.3	5
117	A Whole of Population, Multiuser Series of High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: Outcomes and Implications. <i>Journal of Endourology</i> , 2015, 29, 844-849.	2.1	5
118	Prospective evaluation of patient-reported quality of life outcomes after external beam radiation treatment for prostate cancer in Victoria: A cohort study by the Victorian Prostate Cancer Registry. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 420-427.	1.8	5
119	Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 629-634.e8.	1.9	5
120	The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. <i>Cancers</i> , 2019, 11, 928.	3.7	5
121	Large variation in conservative management of low-risk prostate cancer in Australia and New Zealand. <i>BJU International</i> , 2022, 130, 17-19.	2.5	5
122	Comparison of urinary and sexual patient-reported outcomes between open radical prostatectomy and robot-assisted radical prostatectomy: a propensity score matched, population-based study in Victoria. <i>BMC Urology</i> , 2022, 22, 18.	1.4	5
123	Adjuvant radiotherapy for DCIS. <i>Lancet, The</i> , 2000, 355, 2071.	13.7	4
124	A simple technique for determining accurate urethral dosimetry after seed brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2006, 5, 27-31.	0.5	4
125	Assessing mood and general health-related quality of life among men treated in Australia for localized prostate cancer. <i>International Journal of Urology</i> , 2007, 14, 311-316.	1.0	4
126	Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset. <i>BMC Research Notes</i> , 2016, 9, 37.	1.4	4

#	ARTICLE	IF	CITATIONS
127	Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A population-based analysis. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 649-654.	1.8	4
128	Is Radiotherapy a Good Adjuvant Strategy for Men With a History of Cryptorchism and Stage I Seminoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 65-70.	0.8	3
129	Population-based study of grade progression in patients who harboured Gleason 3+3. <i>World Journal of Urology</i> , 2017, 35, 1689-1699.	2.2	3
130	A Randomized Controlled Trial of an Additional Funding Intervention to Improve Clinical Trial Enrollment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1104-1110.	4.9	3
131	Brachytherapy-based radiotherapy with androgen deprivation for management of high-risk prostate cancer – time to reverse the declining trend?. <i>BJU International</i> , 2018, 122, 5-6.	2.5	3
132	Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 135011.	3.0	3
133	Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e581-e591.	1.9	3
134	External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. <i>Frontiers in Oncology</i> , 2020, 10, 910.	2.8	3
135	TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 5007-5007.	1.6	3
136	Quantifying the effect email reminders have on patient reported outcome measure returns in a large prostate cancer registry. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, 19.	1.9	3
137	Radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. <i>Lancet, The</i> , 1997, 350, 1179.	13.7	2
138	Accrediting radiation technique in a multicentre trial of chemoradiation for pancreatic cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2008, 52, 598-604.	1.8	2
139	Practical considerations in the selection of seed strength for prostate implants. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 53-61.	1.9	2
140	Long-term outcomes following postoperative radiotherapy for Stage I testicular seminoma – an Australasian single-institution experience. <i>Journal of Medical Radiation Sciences</i> , 2016, 63, 161-169.	1.5	2
141	Activation of hip prostheses in high energy radiotherapy and resultant dose to nearby tissue. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 100-105.	1.9	2
142	In Regard to Yang et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1294-1295.	0.8	2
143	Australian validation of the Cancer of the Prostate Risk Assessment Post-surgical score to predict biochemical recurrence after radical prostatectomy. <i>ANZ Journal of Surgery</i> , 2018, 88, E183-E188.	0.7	2
144	Body size and dietary risk factors for aggressive prostate cancer: a case-control study. <i>Cancer Causes and Control</i> , 2019, 30, 1301-1312.	1.8	2

#	ARTICLE	IF	CITATIONS
145	Development of Technologic Solutions to Address Complex Local Requirements of an International Prostate Cancer Clinical Quality Registry. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-11.	2.1	2
146	Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards. <i>Medical Journal of Australia</i> , 2021, 214, 528-531.	1.7	2
147	Evolving Practice Pattern of Palliative Radiation Therapy for Bone Metastases from Lung Cancer in Australia. <i>Clinical Oncology</i> , 2021, 33, e530-e539.	1.4	2
148	Review on bladder cancer. <i>BMJ: British Medical Journal</i> , 1999, 318, 875-875.	2.3	2
149	What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The RAVES phase III randomized clinical trial. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4690-TPS4690.	1.6	2
150	Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. <i>BMC Cancer</i> , 2022, 22, 283.	2.6	2
151	Disparities in radiation therapy utilization for cancer patients in Victoria. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 830-839.	1.8	2
152	Large variation in radiation therapy fractionation for multiple myeloma in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 149-157.	1.1	2
153	Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e060189.	1.9	2
154	In regard to Pollack et al., prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. <i>IJROBP</i> 2002;53:1097-1105. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1461.	0.8	1
155	Characterization of the pattern of sexual function after brachytherapy or radical prostatectomy suggests the importance of expectation management. <i>Brachytherapy</i> , 2008, 7, 121.	0.5	1
156	An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone/Radiation Interactions: In Regard to Lawton et al. ( <i>Int J Radiat Oncol Biol Phys</i> )	0.8	1
157	P331 Transition to Palliative Care for Patients with Metastatic Prostate Cancer: How Well Have We Integrated?. <i>Journal of Pain and Symptom Management</i> , 2016, 52, e150-e151.	1.2	1
158	P333 Integration of Palliative Care for Patients with Metastatic Breast Cancer: Have We Achieved Quality End-of-Life Care?. <i>Journal of Pain and Symptom Management</i> , 2016, 52, e152.	1.2	1
159	PD47-11 OPTIMUM TOOLS FOR PREDICTING CLINICAL OUTCOMES IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY: A SYSTEMATIC REVIEW OF PROGNOSTIC ACCURACY AND VALIDITY. <i>Journal of Urology</i> , 2017, 197, .	0.4	1
160	Interpolation to define clinical tumor stage in prostate cancer using clinical description of digital rectal examination. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e412-e419.	1.1	1
161	Changing pattern of radiation therapy for bone metastases in an Australian population-based cohort of men with prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e7-e15.	1.9	1
162	Monitoring Quality of Care in Men Diagnosed with Prostate Cancer: Developing Consensus Quality Indicators Using Modified-Delphi Methodology. <i>Journal of Epidemiology and Preventive Medicine</i> , 2015, 1, .	0.2	1

#	ARTICLE	IF	CITATIONS
163	Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registry. <i>Psycho-Oncology</i> , 2021, , .	2.3	1
164	Knowledge and insights from a maturing international clinical quality registry. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 964-969.	4.4	1
165	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
166	Radiation oncology peer review in Australia and New Zealand. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 258-266.	1.8	1
167	Codesigning a patient support portal with health professionals and men with prostate cancer: An action research study. <i>Health Expectations</i> , 2022, , .	2.6	1
168	Variations in whole brain radiation therapy fractionation for brain metastases in Victoria. <i>Journal of Medical Imaging and Radiation Oncology</i> , 0, , .	1.8	1
169	Surgery for oesophageal squamous cell carcinoma. <i>Lancet, The</i> , 1994, 343, 1099.	13.7	0
170	Adjuvant radiotherapy for DCIS. <i>Lancet, The</i> , 2000, 355, 2072.	13.7	0
171	Androgen Suppression Plus Radiation for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2581.	7.4	0
172	Alternative explanations for T-cell response to in-situ gene therapy for prostate cancer: In reply to Fugita et al. ( <i>Int J Radiat Oncol Biol Phys</i> 2006;65:84-90). <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1599.	0.8	0
173	Qualitative research to improve patient perception of care: A prostate brachytherapy patient focus group. <i>Brachytherapy</i> , 2008, 7, 193.	0.5	0
174	Re: Finney G, Haynes A-M, Cross P, et al: Cross-Sectional Analysis of Sexual Function After Prostate Brachytherapy ( <i>Urology</i> 66: 377-381, 2005). <i>Urology</i> , 2008, 71, 364.	1.0	0
175	231 SURVIVAL ANALYSIS OF A WHOLE OF POPULATION STUDY FOR RADICAL PROSTATECTOMY IN THE PSA ERA. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
176	Establishing tumour tracking accuracy in free-breathing respiratory gated SBRT of lung cancer. <i>Journal of Physics: Conference Series</i> , 2014, 489, 012041.	0.4	0
177	P332 Exploring the Landscape of Palliative Care for People with Non-Hodgkin's Lymphoma: Do They Receive Quality End-of-Life Care?. <i>Journal of Pain and Symptom Management</i> , 2016, 52, e151-e152.	1.2	0
178	OC-0170: Routine clinical treatment verification in HDR prostate brachytherapy with source tracking. <i>Radiotherapy and Oncology</i> , 2018, 127, S88.	0.6	0
179	Optimal Treatment for High-Risk Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 404.	7.4	0
180	Androgen deprivation therapy use with post-prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 124-130.	1.8	0

#	ARTICLE	IF	CITATIONS
181	Quality-of-life outcomes for prostate cancer treatment in Australia.. Journal of Clinical Oncology, 2013, 31, 143-143.	1.6	0
182	SU-C-16A-01: In Vivo Source Position Verification in High Dose Rate (HDR) Prostate Brachytherapy Using a Flat Panel Imager: Initial Clinical Experience. Medical Physics, 2014, 41, 90-90.	3.0	0
183	Increasing use of post-mastectomy hypofractionated radiation therapy for breast cancer in Victoria. Journal of Medical Imaging and Radiation Oncology, 2021, , .	1.8	0